Re: expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. T. Kurahashi, H. Miyake, I. Hara and M. Fujisawa J Urol 2007; 177: 757-761.
Vale
Salvador
S
D058891:5-alpha Reductase Inhibitors; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use; D055551:HSP27 Heat-Shock Proteins; D006360:Heat-Shock Proteins / Q000378:metabolism*; D006801:Humans; D008297:Male; D018832:Molecular Chaperones; D009363:Neoplasm Proteins / Q000378:metabolism*; D011467:Prostate / Q000378:metabolism* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011794:Quercetin / Q000627:therapeutic use; D015854:Up-Regulation
D058891:5-alpha Reductase Inhibitors; D004791:Enzyme Inhibitors; D055551:HSP27 Heat-Shock Proteins; C057725:HSPB1 protein, human; D006360:Heat-Shock Proteins; D018832:Molecular Chaperones; D009363:Neoplasm Proteins; D018120:Finasteride; D011794:Quercetin